U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H10O3
Molecular Weight 166.1739
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of APOCYNIN

SMILES

COC1=CC(=CC=C1O)C(C)=O

InChI

InChIKey=DFYRUELUNQRZTB-UHFFFAOYSA-N
InChI=1S/C9H10O3/c1-6(10)7-3-4-8(11)9(5-7)12-2/h3-5,11H,1-2H3

HIDE SMILES / InChI

Description

Apocynin, also known as acetovanillone, is a natural organic compound related to vanillin. It has been isolated from a variety of plant sources. Metabolites of apocynin are able to block the activity of NADPH oxidase, thus giving apocynin antioxidant and anti-inflammatory capabilities. Effects of apocynin on the concentration of reactive oxygen and nitrogen species in patients with asthma and chronic obstructive pulmonary disease were investigated in phase I clinical trials. In preclinical models, it was found that apocynin provides neuroprotective effects in models of stroke and Parkinson's disease.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
2963.33 ng/mL
50 mg/kg single, oral
APOCYNIN plasma
Rattus norvegicus
10070 ng/mL
5 mg/kg single, intravenous
APOCYNIN plasma
Rattus norvegicus

AUC

ValueDoseCo-administeredAnalytePopulation
5505.13 ng × h/mL
50 mg/kg single, oral
APOCYNIN plasma
Rattus norvegicus
6614.82 ng × h/mL
5 mg/kg single, intravenous
APOCYNIN plasma
Rattus norvegicus

T1/2

ValueDoseCo-administeredAnalytePopulation
3.47 h
50 mg/kg single, oral
APOCYNIN plasma
Rattus norvegicus
0.067 h
5 mg/kg single, intravenous
APOCYNIN plasma
Rattus norvegicus

Funbound

ValueDoseCo-administeredAnalytePopulation
26.7%
APOCYNIN plasma
Homo sapiens

PubMed

Sample Use Guides

In Vivo Use Guide
In a clinical trial against chronic obstructive pulmonary disease, effects of nebulized apocynin (0.5 mg/ml, 6 ml) were assessed in exhaled breath condensate. In rat models of Parkinson's disease, apocynin was administered intraperitoneally at 10 mg/kg. In a model of rheumatoid arthritis, apocynin was administered orally.
Route of Administration: Other
In Vitro Use Guide
The NADPH oxidase inhibitory activity of apocynin and products of its oxidation (AOP) was assessed in an endothelial cell-based assay by measuring the generation of •O2− via cytochrome c reduction. Apocynin itself possesses minimal inhibitory activity (IC50 > 1 mM), while the extracted water-soluble phase of its metabolites exhibited an apparent IC50 value of 155 nM.